| 1 |
33401995 |
10.1080/08820139.2020.1863982 |
2022 |
The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS). |
PIK3CD |
| 2 |
33782541 |
10.1038/s41401-021-00644-1 |
2022 |
SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma. |
PIK3CD |
| 3 |
34688842 |
10.1016/j.canlet.2021.10.022 |
2022 |
Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. |
PIK3CD |
| 4 |
34992612 |
10.3389/fimmu.2021.813261 |
2022 |
Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome. |
PIK3CD |
| 5 |
35021606 |
10.3324/haematol.2021.280003 |
2022 |
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. |
PIK3CD |
| 6 |
35084470 |
10.1182/blood.2021011597 |
2022 |
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. |
PIK3CD |
| 7 |
35247100 |
10.1007/s00277-022-04809-8 |
2022 |
Successful treatment for diffuse large B-cell lymphoma in a Japanese adolescent with PIK3CD germ-line mutation: stem cell transplantation after reduced-intensity conditioning. |
PIK3CD |
| 8 |
35687490 |
10.1182/bloodadvances.2021006654 |
2022 |
Genomic characterization of lymphomas in patients with inborn errors of immunity. |
PIK3CD |
| 9 |
35990641 |
10.3389/fimmu.2022.937872 |
2022 |
Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency. |
PIK3CD |
| 10 |
31964785 |
10.1158/1078-0432.CCR-19-3061 |
2021 |
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. |
PIK3CD |
| 11 |
32603749 |
10.1016/j.jid.2020.05.110 |
2021 |
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. |
PIK3CD |
| 12 |
32784091 |
10.1016/j.bmcl.2020.127479 |
2021 |
Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors. |
PIK3CD |
| 13 |
32992346 |
10.1055/a-1252-2476 |
2021 |
DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study. |
PIK3CD |
| 14 |
33142237 |
10.1016/j.neo.2020.10.004 |
2021 |
SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. |
PIK3CD |
| 15 |
33297683 |
10.1021/acs.jmedchem.0c01264 |
2021 |
Discovery of a Potent and Selective PI3Kδ Inhibitor (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models. |
PIK3CD |
| 16 |
33467550 |
10.3390/ijms22020819 |
2021 |
Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2. |
PIK3CD |
| 17 |
33786583 |
10.1182/blood.2020010187 |
2021 |
Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. |
PIK3CD |
| 18 |
34173009 |
10.1007/s00262-021-02988-3 |
2021 |
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells. |
PIK3CD |
| 19 |
34249806 |
10.3389/fped.2021.652405 |
2021 |
Activated PI3Kinase Delta Syndrome-A Multifaceted Disease. |
PIK3CD |
| 20 |
34352450 |
10.1016/j.jaip.2021.07.044 |
2021 |
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort. |
PIK3CD |
| 21 |
34447369 |
10.3389/fimmu.2021.671755 |
2021 |
Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. |
PIK3CD |
| 22 |
29336479 |
10.1002/jcp.26474 |
2020 |
Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway. |
PIK3CD |
| 23 |
30619796 |
10.3389/fped.2018.00402 |
2020 |
Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion. |
PIK3CD |
| 24 |
30779244 |
10.1002/gcc.22743 |
2020 |
A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis. |
PIK3CD |
| 25 |
30819916 |
10.3324/haematol.2018.212811 |
2020 |
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. |
PIK3CD |
| 26 |
31033788 |
10.1097/MPH.0000000000001487 |
2020 |
A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma. |
PIK3CD |
| 27 |
31355927 |
10.1111/bjh.16118 |
2020 |
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. |
PIK3CD |
| 28 |
31490009 |
10.1002/ajh.25634 |
2020 |
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. |
PIK3CD |
| 29 |
31506873 |
10.1007/s11523-019-00668-y |
2020 |
Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models. |
PIK3CD |
| 30 |
31942637 |
10.1182/blood.2019002072 |
2020 |
Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma. |
PIK3CD |
| 31 |
32443356 |
10.1097/MD.0000000000020232 |
2020 |
Genetic heterogeneity of pediatric systemic lupus erythematosus with lymphoproliferation. |
PIK3CD |
| 32 |
33067957 |
10.19746/j.cnki.issn.1009-2137.2020.05.025 |
2020 |
[Mechanism of MiR-224 Affecting DLBCL Cell Proliferation and Invasion by Targeted Inhibition of PIK3CD]. |
PIK3CD |
| 33 |
29191916 |
10.1182/blood-2017-05-786566 |
2019 |
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. |
PIK3CD |
| 34 |
29233821 |
10.1182/blood-2017-08-802470 |
2019 |
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. |
PIK3CD |
| 35 |
29246942 |
10.1158/1078-0432.CCR-17-2218 |
2019 |
Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies. |
PIK3CD |
| 36 |
29386194 |
10.1182/bloodadvances.2017011254 |
2019 |
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists. |
PIK3CD |
| 37 |
29453281 |
10.4049/jimmunol.1700323 |
2019 |
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. |
PIK3CD |
| 38 |
29472356 |
10.3324/haematol.2017.184325 |
2019 |
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. |
PIK3CD |
| 39 |
29479062 |
10.1038/s41375-018-0012-5 |
2019 |
Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration. |
PIK3CD |
| 40 |
29674500 |
10.3324/haematol.2018.191601 |
2019 |
Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sites. |
PIK3CD |
| 41 |
29695516 |
10.1182/blood-2017-10-812701 |
2019 |
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. |
PIK3CD |
| 42 |
29800648 |
10.1016/j.jaci.2018.04.030 |
2019 |
Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. |
PIK3CD |
| 43 |
30322870 |
10.1182/blood-2018-08-872465 |
2019 |
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. |
PIK3CD |
| 44 |
30723478 |
10.3389/fimmu.2018.03135 |
2019 |
CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID. |
PIK3CD |
| 45 |
30878826 |
10.1016/j.ejmech.2019.03.005 |
2019 |
Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies. |
PIK3CD |
| 46 |
31045771 |
10.1097/MD.0000000000015329 |
2019 |
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report. |
PIK3CD |
| 47 |
31137964 |
10.2217/fon-2018-0881 |
2019 |
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. |
PIK3CD |
| 48 |
27229530 |
10.18632/oncotarget.9568 |
2018 |
High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. |
PIK3CD |
| 49 |
28327905 |
10.1093/annonc/mdx028 |
2018 |
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma. |
PIK3CD |
| 50 |
28716817 |
10.1158/1535-7163.MCT-17-0141 |
2018 |
PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature. |
PIK3CD |
| 51 |
28835371 |
10.1158/1541-7786.MCR-17-0026 |
2018 |
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. |
PIK3CD |
| 52 |
28842185 |
10.1016/j.imlet.2017.08.021 |
2018 |
Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen. |
PIK3CD |
| 53 |
28864640 |
10.1158/2159-8290.CD-17-0714 |
2018 |
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap. |
PIK3CD |
| 54 |
29434192 |
10.1038/s41408-018-0055-x |
2018 |
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. |
PIK3CD |
| 55 |
29472546 |
10.1038/s41408-018-0056-9 |
2018 |
CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL. |
PIK3CD |
| 56 |
26961147 |
10.1093/annonc/mdw131 |
2017 |
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. |
PIK3CD |
| 57 |
26968534 |
10.1182/blood-2015-12-683516 |
2017 |
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. |
PIK3CD |
| 58 |
27448819 |
10.1007/s13277-016-5225-5 |
2017 |
PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc. |
PIK3CD |
| 59 |
27461063 |
10.1038/leu.2016.202 |
2017 |
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. |
PIK3CD |
| 60 |
27555459 |
10.1016/j.jaci.2016.06.021 |
2017 |
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. |
PIK3CD |
| 61 |
28073005 |
10.1016/j.ccell.2016.12.003 |
2017 |
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT. |
PIK3CD |
| 62 |
28112970 |
10.1080/14737140.2017.1285702 |
2017 |
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. |
PIK3CD |
| 63 |
28122867 |
10.1158/2159-8290.CD-16-0330 |
2017 |
The Genetic Basis of Hepatosplenic T-cell Lymphoma. |
PIK3CD |
| 64 |
28178345 |
10.1371/journal.pone.0171221 |
2017 |
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. |
PIK3CD |
| 65 |
28199309 |
10.1038/nature21406 |
2017 |
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. |
PIK3CD |
| 66 |
28280276 |
10.1038/leu.2017.80 |
2017 |
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. |
PIK3CD |
| 67 |
28339079 |
10.3892/ijo.2017.3923 |
2017 |
A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-κB. |
PIK3CD |
| 68 |
28373165 |
10.1158/2159-8290.CD-17-0160 |
2017 |
It Takes a Village to Unmask HSTL. |
PIK3CD |
| 69 |
28424165 |
10.1182/blood-2017-02-766204 |
2017 |
Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. |
PIK3CD |
| 70 |
28777460 |
10.1002/jcp.26135 |
2017 |
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. |
PIK3CD |
| 71 |
28945111 |
10.1080/13543784.2017.1384815 |
2017 |
PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. |
PIK3CD |
| 72 |
25670221 |
10.1158/1078-0432.CCR-14-2034 |
2016 |
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. |
PIK3CD |
| 73 |
25712626 |
10.1177/1078155215572933 |
2016 |
Idelalisib- a PI3Kδ targeting agent for B-cell malignancies. |
PIK3CD |
| 74 |
26426383 |
10.1097/PAS.0000000000000525 |
2016 |
Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides. |
PIK3CD |
| 75 |
26448188 |
10.1097/PAS.0000000000000522 |
2016 |
Idelalisib-associated Colitis: Histologic Findings in 14 Patients. |
PIK3CD |
| 76 |
25326077 |
10.1517/13543776.2014.969710 |
2015 |
Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings. |
PIK3CD |
| 77 |
26081031 |
10.1615/jenvironpatholtoxicoloncol.2015013477 |
2015 |
Attenuation of Leukemia/Lymphoma-Related Factor Protein Expression Inhibits Glioma Cell Proliferation and Invasion. |
PIK3CD |
| 78 |
26535063 |
10.7150/jca.11279 |
2015 |
The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma. |
PIK3CD |
| 79 |
22801959 |
10.3324/haematol.2012.068510 |
2014 |
Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. |
PIK3CD |
| 80 |
24610295 |
10.1007/s10875-014-0012-9 |
2014 |
Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. |
PIK3CD |
| 81 |
24642682 |
10.1038/nrclinonc.2014.42 |
2014 |
Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies. |
PIK3CD |
| 82 |
24651009 |
10.1016/j.ccr.2014.02.012 |
2014 |
PI3Kδ inhibition hits a sensitive spot in B cell malignancies. |
PIK3CD |
| 83 |
24698326 |
10.1016/j.jaci.2014.02.020 |
2014 |
Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome. |
PIK3CD |
| 84 |
24809089 |
10.1016/s1470-2045(14)70052-x |
2014 |
Idelalisib: targeting PI3Kδ in B-cell malignancies. |
PIK3CD |
| 85 |
23215766 |
10.3109/08830185.2012.737073 |
2013 |
HIV-1 Nef in macrophage-mediated disease pathogenesis. |
PIK3CD |
| 86 |
23292937 |
10.1073/pnas.1205299110 |
2013 |
Genetic heterogeneity of diffuse large B-cell lymphoma. |
PIK3CD |
| 87 |
23341541 |
10.1182/blood-2012-10-460832 |
2013 |
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. |
PIK3CD |
| 88 |
22112004 |
10.1517/13543784.2012.640318 |
2012 |
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. |
PIK3CD |
| 89 |
22210877 |
10.1182/blood-2011-10-386763 |
2012 |
PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. |
PIK3CD |
| 90 |
22516257 |
10.1016/j.ccr.2012.02.029 |
2012 |
Targeting nonclassical oncogenes for therapy in T-ALL. |
PIK3CD |
| 91 |
20826752 |
10.4049/jimmunol.1001730 |
2010 |
Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. |
PIK3CD |
| 92 |
17371233 |
10.1042/BST0350183 |
2007 |
p110delta is required for innate immunity to transplantable lymphomas. |
PIK3CD |
Datasets
Models
